PUBLISHER: The Business Research Company | PRODUCT CODE: 1970109
PUBLISHER: The Business Research Company | PRODUCT CODE: 1970109
Artificial intelligence is applied in cardiology to predict cardiovascular outcomes, identify malignant arrhythmias, and non-invasively diagnose coronary artery disease. Its use encompasses the detection of heart disease, prompt stroke treatment, and the improvement of diagnostic radiology capabilities.
The essential components of artificial intelligence in cardiology include hardware, software solutions, and services. Hardware pertains to the components or delivery mechanisms responsible for storing and executing written instructions from specific software. In cardiology, artificial intelligence hardware is employed in treating various cardiovascular diseases, such as cardiac arrhythmia, stroke, ischemic heart disease, and coronary artery disease (CAD). Life science companies, healthcare payers, and healthcare providers utilize these technologies.
Tariffs have influenced the AI in cardiology market by increasing costs for imported imaging equipment, wearable devices, and diagnostic hardware. These impacts are strongest in hospital and specialty clinic segments, particularly in asia pacific and north america. Elevated equipment prices have affected technology upgrades. However, tariffs are encouraging local device manufacturing, regional supplier development, and software led cardiology innovations.
The artificial intelligence in cardiology market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence in cardiology market statistics, including artificial intelligence in cardiology industry global market size, regional shares, competitors with a artificial intelligence in cardiology market share, detailed artificial intelligence in cardiology market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in cardiology industry. This artificial intelligence in cardiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The artificial intelligence in cardiology market size has grown exponentially in recent years. It will grow from $2.72 billion in 2025 to $3.82 billion in 2026 at a compound annual growth rate (CAGR) of 40.7%. The growth in the historic period can be attributed to rising cardiovascular disease prevalence, early adoption of cardiac imaging software, growth of wearable medical devices, demand for faster diagnosis, expansion of digital healthcare infrastructure.
The artificial intelligence in cardiology market size is expected to see exponential growth in the next few years. It will grow to $15.19 billion in 2030 at a compound annual growth rate (CAGR) of 41.2%. The growth in the forecast period can be attributed to remote patient monitoring adoption, AI driven clinical decision support, personalized cardiology treatments, integration of telecardiology platforms, focus on preventive cardiac care. Major trends in the forecast period include AI based cardiac imaging analysis, growth of predictive cardiology analytics, integration of wearable heart monitoring, automation of arrhythmia detection, expansion of remote cardiac care solutions.
The substantial burden of cardiovascular diseases is anticipated to drive the growth of the artificial intelligence in cardiology market in the coming years. Cardiovascular diseases include all conditions that affect the heart and blood vessels. In cardiology, AI is utilized to identify cardiovascular disorders by supporting electrocardiogram (ECG) analysis and aiding in the detection of conditions such as long QT syndrome and atrial fibrillation. In addition, AI can analyze vast volumes of data from electronic health records, mobile health devices, and imaging systems. For instance, in August 2025, according to the American Cancer Society, a US-based non-profit organization, cardiovascular disease prevalence is projected to rise by 90.0% between 2025 and 2050. Moreover, in October 2024, as reported by the Centres for Disease Control and Prevention (CDC), a US-based federal health agency, 919,032 deaths were attributed to cardiovascular disease in the United States in 2023, accounting for nearly 1 in every 3 deaths. Hence, the heavy burden of cardiovascular diseases is accelerating the growth of artificial intelligence (AI) in cardiology.
Major companies operating in the artificial intelligence in cardiology market are increasingly emphasizing strategic collaborations to advance cardiovascular research. Strategic partnerships involve companies combining their strengths and resources to achieve shared benefits and success. For example, in October 2023, the Icahn School of Medicine at Mount Sinai, a US-based medical school, announced a collaboration with the Chiba Institute of Technology (CIT), a Japan-based private university. This partnership aims to enhance understanding, prevention, and management of cardiovascular disease while developing innovative approaches to address this global health challenge. Mount SinAI and CIT plan to work together on global clinical studies involving artificial intelligence and interventional cardiology, heart failure, cardiac electrophysiology, cardiac imaging, and preventive cardiology. The collaboration will also emphasize reducing gender and racial bias at the intersection of artificial intelligence and cardiovascular research to improve patient outcomes and care.
In August 2024, Stryker Corporation, a US-based medical technology company, acquired Care.AI for an undisclosed amount. Through this acquisition, Stryker intends to reinforce its digital healthcare ecosystem by integrating Care.ai's AI-enabled sensor technology and virtual-care workflow solutions into its connected medical device portfolio. Care.AI is a US-based healthcare technology firm that uses artificial intelligence to strengthen patient monitoring and clinical decision-making across cardiology and other medical specialties.
Major companies operating in the artificial intelligence in cardiology market are Microsoft Corporation; International Business Machines Corporation; Siemens Healthineers; Koninklijke Philips; Ultromics Ltd; Bay Labs; Cleerly Inc.; RSIP Vision Ltd.; Idoven; Cardiologs Technologies Inc.; Viz.ai; Aidoc; Arterys Inc.; Zebra Medical Vision; AliveCor; DiA Imaging Analysis; Eko Health Inc.; Cardiomatics; UltraSight; Anumana Inc.; CardiAI Inc.; Caption Health Inc.; HeartFlow Inc.; iRhythm Technologies Inc.; Biofourmis Inc.
North America was the largest region in the artificial intelligence in cardiology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in cardiology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the artificial intelligence in cardiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The artificial intelligence in cardiology market consists of revenues earned by entities by providing disease prediction, disease diagnosis, and automation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence market in cardiology also includes sales of smart robots, and imaging tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Artificial Intelligence In Cardiology Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses artificial intelligence in cardiology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for artificial intelligence in cardiology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence in cardiology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.